Alter Pharma Group Rebrands As A.forall
Rebranding Includes US Niche Injectables And Solutions Firm Milla Pharmaceuticals
Alter Pharma Group – including its US generics operation Milla Pharmacuticals, focused on niche injectables and solutions – has rebranded as A.forall.
You may also be interested in...
European off-patent industry association Medicines for Europe has welcomed the European Parliament’s “balanced stand” on unitary SPC regulation after “safeguard” provisions allowing pre-grant opposition and explicitly banning patent linkage were adopted.
Biocon Biologics has secured a launch date for its planned US biosimilar to Stelara that puts it ahead of some of the competition.
Alvotech has announced a share sale that will raise $166m for the biosimilars developer, in the wake of its recent US Food and Drug Administration approval for its AVT02 adalimumab biosimilar, Simlandi.